THE Therapeutic Goods Administration has kicked off legal action against Peptide Clinics Australia, claiming the company advertised compounded prescription-only therapeutic goods to the general public.
The TGA investigated the company's advertising of 'peptides' on its website and other social media platforms, saying it included references to serious forms of diseases and to conditions such as anxiety and depression.
"These references require approvals or permissions, for which it is alleged there are none," the TGA advised.
The advertising is also alleged to be in breach of the Therapeutic Goods Advertising Code 2015 because it contained statements, claims and implications that the advertised peptides were safe or alternatively could not cause harm, and encouraged inappropriate use of the medicines.
"The promotion of these peptides to consumers is also alleged to have contained scientific information that was inaccurate, imbalanced and misleading," the TGA said.
Peptide Clinics has undertaken to remove the relevant advertisements from its website pending final hearing of the matter, while the Department of Health said the Court will be asked to impose financial penalties when the matter is heard next year.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Dec 18
